Skip to content
  • Email:
info@kitherbiotech.com
  • Tel:

XXXXXXX

  • Address:
Via Nizza 52, Torino (Italia)
Kither Biotech
  • Home
  • About Us
    • Company Overview
    • Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Drug development
    • Publications
  • Pipeline
    • KIT2014
    • KITCL27
  • Media
    • Press releases
    • Press coverage
  • Careers
  • Contact
  • Home
  • About Us
    • Company Overview
    • Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Drug development
    • Publications
  • Pipeline
    • KIT2014
    • KITCL27
  • Media
    • Press releases
    • Press coverage
  • Careers
  • Contact
×
  • Home
  • About Us
    • Company Overview
    • Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Drug development
    • Publications
  • Pipeline
    • KIT2014
    • KITCL27
  • Media
    • Press releases
    • Press coverage
  • Careers
  • Contact

“A PI3Kγ mimetic peptide triggers CFTR gating, brochodilation, and reduced inflammation in obstructive airway diseases”

Ghigo et al (& Sala, Hirsch), Science Translational Medicine

“A non-catalytic function of PI3Kγ drives smooth muscle cell proliferation after arterial damage”

Lupieri et al (& Ghigo, Hirsch), Journal of Cell Science.

“Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis”

Campa et al (& Sala, Hirsch), Nature Communications.

“Identification of a Potent Phosphoinositide 3-Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs”.

Pirali et al (& Hirsch), ChemMedChem.

“Phosphoinositide 3-kinase γ protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases”

Ghigo et al (& Hirsch), Circulation.

“Distinct Effects of Leukocyte and Cardiac Phosphoinositide 3-Kinase {gamma} Activity in Pressure Overload-Induced Cardiac Failure”

Damilano et al (& Ghigo, Hirsch), Circulation.

“Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma”

Vecchione et al (& Hirsch), Journal of Experimental Medicine.

“PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects”

Patrucco et al (& Hirsch), Cell.

“Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation”

Hirsch et al, Science.

Recent articles

  • Kither Biotech announces publication of new data in Science Translational Medicine
  • Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer
  • Kither Biotech welcomes Dr. Vincent Metzler as new Member of the Board
  • Kither Biotech raises a €5.6m financing round to support the clinical development of a new drug for cystic fibrosis and other pulmonary diseases
Kither Biotech
Kither Biotech is a biopharmaceutical company developing signal transduction modulators for the treatment of rare respiratory diseases.
Linkedin Youtube
Menu
  • Home
  • About Us
    • Company Overview
    • Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Drug development
    • Publications
  • Pipeline
    • KIT2014
    • KITCL27
  • Media
    • Press releases
    • Press coverage
  • Careers
  • Contact
×
  • Home
  • About Us
    • Company Overview
    • Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Drug development
    • Publications
  • Pipeline
    • KIT2014
    • KITCL27
  • Media
    • Press releases
    • Press coverage
  • Careers
  • Contact
Contact
  • Via Nizza 52, Torino (Italia)
  • info@kitherbiotech.com
Useful information
  • Privacy Policy
  • Cookie Policy
KITHER BIOTECH S.R.L. © COPYRIGHT 2021-2022. P. IVA 10615040010. DESIGN BY WEB AGENCY TORINO – WEB BRAND